Does the media refer more to RYTM or SEPN?

In the previous week, Rhythm Pharmaceuticals had 15 more articles in the media than Septerna. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Septerna 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SEPN or CGON?

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 39.30 -$48.88M -$0.54 N/A CG Oncology $4.04M 1,637.21 -$160.99M -$2.69 N/A

Is SEPN or CGON more profitable?

Septerna has a net margin of -24.51% compared to CG Oncology's net margin of -3,602.68%. Septerna's return on equity of -9.57% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -24.51% -9.57% -6.28% CG Oncology -3,602.68% -25.20% -23.98%

Does the media favor SEPN or CGON?

In the previous week, CG Oncology had 6 more articles in the media than Septerna. MarketBeat recorded 8 mentions for CG Oncology and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat CG Oncology's score of 0.56 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or SEPN?

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Septerna. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Mirum Pharmaceuticals' score of 0.62 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SEPN or ORKA?

In the previous week, Oruka Therapeutics had 13 more articles in the media than Septerna. MarketBeat recorded 15 mentions for Oruka Therapeutics and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Oruka Therapeutics' score of 0.26 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SEPN or TVTX?

In the previous week, Travere Therapeutics had 35 more articles in the media than Septerna. MarketBeat recorded 37 mentions for Travere Therapeutics and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Travere Therapeutics' score of 0.34 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 16 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Septerna (SEPN) Competitors

$38.69 -0.81 (-2.05%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$38.72 +0.03 (+0.08%)

As of 09/18/2026 07:30 PM Eastern

Compare

SEPN vs. RYTM, CGON, MIRM, ORKA, and TVTX

Should you buy Septerna stock or one of its competitors? Septerna's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Oruka Therapeutics (ORKA), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Septerna compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Septerna has a net margin of -24.51% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Septerna's return on equity of -9.57% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Septerna	-24.51%	-9.57%	-6.28%

Rhythm Pharmaceuticals presently has a consensus target price of $140.67, suggesting a potential upside of 43.96%. Septerna has a consensus target price of $52.44, suggesting a potential upside of 35.55%. Given Rhythm Pharmaceuticals' higher possible upside, equities research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Septerna has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	35.29	-$196.54M	-$3.11	N/A
Septerna	$45.95M	39.30	-$48.88M	-$0.54	N/A

Rhythm Pharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market. Comparatively, Septerna has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 15 more articles in the media than Septerna. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Septerna beats Rhythm Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Septerna compare to CG Oncology?

Septerna (NASDAQ:SEPN) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

26.6% of CG Oncology shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Septerna presently has a consensus price target of $52.44, indicating a potential upside of 35.55%. CG Oncology has a consensus price target of $87.78, indicating a potential upside of 17.63%. Given Septerna's stronger consensus rating and higher probable upside, equities analysts plainly believe Septerna is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Septerna has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

In the previous week, CG Oncology had 6 more articles in the media than Septerna. MarketBeat recorded 8 mentions for CG Oncology and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat CG Oncology's score of 0.56 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	39.30	-$48.88M	-$0.54	N/A
CG Oncology	$4.04M	1,637.21	-$160.99M	-$2.69	N/A

Septerna has a net margin of -24.51% compared to CG Oncology's net margin of -3,602.68%. Septerna's return on equity of -9.57% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Summary

Septerna beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does Septerna compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Mirum Pharmaceuticals currently has a consensus price target of $137.31, indicating a potential upside of 49.53%. Septerna has a consensus price target of $52.44, indicating a potential upside of 35.55%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Mirum Pharmaceuticals has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Septerna has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Septerna. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Mirum Pharmaceuticals' score of 0.62 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has a net margin of -24.51% compared to Mirum Pharmaceuticals' net margin of -139.18%. Septerna's return on equity of -9.57% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Septerna	-24.51%	-9.57%	-6.28%

Mirum Pharmaceuticals has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A
Septerna	$45.95M	39.30	-$48.88M	-$0.54	N/A

Summary

Mirum Pharmaceuticals and Septerna tied by winning 7 of the 14 factors compared between the two stocks.

How does Septerna compare to Oruka Therapeutics?

Septerna (NASDAQ:SEPN) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Oruka Therapeutics had 13 more articles in the media than Septerna. MarketBeat recorded 15 mentions for Oruka Therapeutics and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Oruka Therapeutics' score of 0.26 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Septerna has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market.

Septerna presently has a consensus target price of $52.44, indicating a potential upside of 35.55%. Oruka Therapeutics has a consensus target price of $133.00, indicating a potential upside of 40.06%. Given Oruka Therapeutics' higher probable upside, analysts clearly believe Oruka Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Septerna has higher revenue and earnings than Oruka Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	39.30	-$48.88M	-$0.54	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

56.4% of Oruka Therapeutics shares are held by institutional investors. 5.8% of Septerna shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Septerna beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Septerna compare to Travere Therapeutics?

Septerna (NASDAQ:SEPN) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Travere Therapeutics has a net margin of -7.35% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Travere Therapeutics has higher revenue and earnings than Septerna. Travere Therapeutics is trading at a lower price-to-earnings ratio than Septerna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	39.30	-$48.88M	-$0.54	N/A
Travere Therapeutics	$490.73M	12.06	-$25.55M	-$0.46	N/A

Septerna has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Septerna currently has a consensus price target of $52.44, indicating a potential upside of 35.55%. Travere Therapeutics has a consensus price target of $68.00, indicating a potential upside of 8.35%. Given Septerna's stronger consensus rating and higher probable upside, equities research analysts plainly believe Septerna is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Travere Therapeutics had 35 more articles in the media than Septerna. MarketBeat recorded 37 mentions for Travere Therapeutics and 2 mentions for Septerna. Septerna's average media sentiment score of 0.67 beat Travere Therapeutics' score of 0.34 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	16 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Septerna beats Travere Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Septerna News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SEPN vs. The Competition

Export

Metric	Septerna	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.81B	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-71.65	14.23	274.93	25.38
Price / Sales	39.30	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	4.54	15.45	10.46	6.33
Net Income	-$48.88M	-$22.86M	$3.49B	$358.33M
7 Day Performance	0.47%	-1.21%	0.59%	1.12%
1 Month Performance	-5.15%	-3.29%	-1.74%	-2.39%
1 Year Performance	146.43%	37.74%	18.13%	5.35%

Septerna Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SEPN Septerna	3.0057 of 5 stars	$38.69 -2.1%	$52.44 +35.6%	+146.4%	$1.81B	$45.95M	N/A	130
RYTM Rhythm Pharmaceuticals	2.7622 of 5 stars	$101.80 -0.9%	$141.12 +38.6%	+1.7%	$6.98B	$239.92M	N/A	140	News Coverage Analyst Forecast
CGON CG Oncology	2.8453 of 5 stars	$73.40 -1.7%	$87.78 +19.6%	+102.2%	$6.51B	$4.04M	N/A	61	News Coverage
MIRM Mirum Pharmaceuticals	3.0345 of 5 stars	$99.53 -1.4%	$137.31 +38.0%	+23.5%	$6.46B	$521.31M	N/A	140
ORKA Oruka Therapeutics	3.4315 of 5 stars	$94.31 +1.9%	$133.00 +41.0%	+510.7%	$6.24B	N/A	N/A	N/A	Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SEPN) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Septerna (SEPN) Competitors

SEPN vs. RYTM, CGON, MIRM, ORKA, and TVTX

How does Septerna compare to Rhythm Pharmaceuticals?

Summary

How does Septerna compare to CG Oncology?

Summary

How does Septerna compare to Mirum Pharmaceuticals?

Summary

How does Septerna compare to Oruka Therapeutics?

Summary

How does Septerna compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Septerna (SEPN) Competitors

SEPN vs. RYTM, CGON, MIRM, ORKA, and TVTX

How does Septerna compare to Rhythm Pharmaceuticals?

Is RYTM or SEPN more profitable?

Do analysts prefer RYTM or SEPN?

Which has higher earnings & valuation, RYTM or SEPN?

Which has more volatility & risk, RYTM or SEPN?

Does the media refer more to RYTM or SEPN?

Summary

How does Septerna compare to CG Oncology?

Do institutionals & insiders believe in SEPN or CGON?

Do analysts recommend SEPN or CGON?

Which has more volatility and risk, SEPN or CGON?

Does the media favor SEPN or CGON?

Which has better valuation and earnings, SEPN or CGON?

Is SEPN or CGON more profitable?

Summary

How does Septerna compare to Mirum Pharmaceuticals?

Do analysts recommend MIRM or SEPN?

Which has more volatility & risk, MIRM or SEPN?

Does the media favor MIRM or SEPN?

Is MIRM or SEPN more profitable?

Which has higher earnings & valuation, MIRM or SEPN?

Summary

How does Septerna compare to Oruka Therapeutics?

Does the media favor SEPN or ORKA?

Which has more risk & volatility, SEPN or ORKA?

Do analysts recommend SEPN or ORKA?

Is SEPN or ORKA more profitable?

Which has preferable earnings and valuation, SEPN or ORKA?

Do insiders & institutionals believe in SEPN or ORKA?

Summary

How does Septerna compare to Travere Therapeutics?

Is SEPN or TVTX more profitable?

Which has stronger valuation and earnings, SEPN or TVTX?

Which has more risk and volatility, SEPN or TVTX?

Do analysts prefer SEPN or TVTX?

Does the media favor SEPN or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools